News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
marketbeat.com Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Genelux Corporation announced its second-quarter 2026 financial results and provided business updates, including anticipated topline data from its Phase 3 OnPrime/GOG-3076 ovarian cancer trial in the second half of 2026. The company reported $18.7 million in cash, cash equivalents, marketable securities, and restricted cash …
Genelux Corp (GNLX) has an earnings forecast score of 8.00, placing it 171st in the Biotechnology & Medical Research industry. Analysts have set an average price target of $18.00 for GNLX, with a range from $10.00 to $31.00. Based on ratings from 6 analysts, …
Despite a recent 11% drop in Genelux Corporation's value, insiders who sold US$181k worth of stock over the last year would have been better off holding, as their average selling price of US$3.34 is higher than the current US$2.51 share price. There have been …
Genelux Corp (GNLX) is expected to report a loss of 20 cents per share in its upcoming earnings. This forecast is based on information from Refinitiv. The article provides an earnings preview for the company.
This article provides a technical analysis of Genelux Corp (GNLX), detailing its price momentum score of 3.33 and its trading range between a resistance of $3.15 and support of $2.75. It reviews various technical indicators like MACD, RSI, and Moving Averages, concluding with a …
This article provides a financial health analysis of Genelux Corp (GNLX), assigning it a TradingKey financial score of 7.03, ranking 153 out of 384 in the Biotechnology & Medical Research industry. The company's financial status is deemed stable with low operating efficiency. The analysis …
The article analyzes the institutional confidence score for Genelux Corp (GNLX), which is currently 3.00, ranking it 192 out of 384 in the Biotechnology & Medical Research industry. The institutional shareholding proportion has increased by 14.81% quarter-over-quarter, reaching 30.96%. James Simons is identified as …
This article provides a risk assessment for Genelux Corp (GNLX), highlighting its current stock performance and risk score. GNLX has a risk assessment score of 1.61, ranking 279 out of 384 in the Biotechnology & Medical Research industry, with a beta of 0.54, indicating …
The article provides a valuation analysis for Genelux Corp (GNLX), noting its current valuation score of 6.14, which ranks 343 out of 385 in the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -3.43, indicating a decrease of 49.87% …
This article provides a detailed financial overview of Genelux Corp (GNLX), presenting its income statement, balance sheet, and cash flow data. It highlights key financial indicators such as EPS, revenue, net profit, assets, liabilities, and equity for various fiscal quarters and years. The report …
This article provides the cash flow statement for Genelux Corp (GNLX), detailing its operating, investing, and financing cash flows on a quarterly and annual basis. It includes key figures like net income, capital expenditures, and free cash flow, alongside answers to frequently asked questions …
This article details the shareholder structure of Genelux Corp (GNLX), identifying both major individual shareholders and institutional holdings. It provides a breakdown of shareholder types, institutional shareholding trends over recent quarters, and a list of top shareholder activities with changes in their holdings. The …
This article provides an overview of Genelux Corp (GNLX) stock performance, showing its current price and market capitalization. It highlights that the company has not distributed any dividends over the past five years, with no historical dividend data available. The content focuses purely on …
This article provides a detailed quarterly income statement for Genelux Corp (GNLX), covering financial performance metrics from FY2021Q1 to FY2026Q1. It includes data on total revenue, operating expenses, R&D expenses, operating profit, net income, and earnings per share, along with year-over-year comparisons. The page …
This article from TradingKey attempts to provide a revenue breakdown for Genelux Corp (GNLX) but states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. It primarily serves as a placeholder indicating the absence …
Search by ticker symbol or company name and select a result to open its chart.